{
    "nctId": "NCT00755313",
    "briefTitle": "Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer",
    "officialTitle": "Effects of Chemotherapy on Brain Structure and Function",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 81,
    "primaryOutcomeMeasure": "Change in glucose metabolism",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer, meeting 1 of the following criteria:\n\n  * Group A\n\n    * Stage I, II, or III invasive disease\n    * Hormone receptor-positive disease\n    * Planned adjuvant chemotherapy including an anthracycline and taxane using either dose-dense or docetaxel, doxorubicin hydrochloride, and cyclophosphamide (TAC) regimens with or without trastuzumab (Herceptin\u00ae) for 4 months; docetaxel and cyclophosphamide (TC) with or without trastuzumab for 3 months; doxorubicin hydrochloride and cyclophosphamide (AC) for 3 months; or doxorubicin hydrochloride, carboplatin, and trastuzumab (TCH) for 4 months (trastuzumab may be given for 1 year and is not considered chemotherapy for the purpose of this study)\n    * Planned treatment with adjuvant aromatase inhibitors (AI) for 5 years\n  * Group B\n\n    * Stage I or II invasive disease\n    * Planned treatment with adjuvant AI with or without radiotherapy\n  * Group C\n\n    * Stage I, II, or III disease\n    * Hormone-receptor negative\n    * Planned adjuvant chemotherapy as in group A\n    * No treatment with AI planned\n  * Group D\n\n    * Healthy controls free of any major medical or psychiatric disorders\n    * Not taking prescription medications, including hormone-replacement therapy, or other substances that might influence performance on neuropsychological tests\n    * Balanced with the patient groups on age, education, ethnicity, and sociodemographic background\n\nPATIENT CHARACTERISTICS:\n\n* No history of psychiatric illness other than minor depression\n* No history of psychiatric illness other than minor depression in immediate family members\n* No history of neurologic disease\n* No history of drug or alcohol abuse\n* No significant medical illness other than breast cancer\n* No heart pacemaker or metallic implants or particles in the body\n* No heart rhythm disturbance\n* No claustrophobia\n* No prior serious head injury\n* No tattoos or permanent cosmetics\n* No unremovable body jewelry\n* No cognitive impairment\n* Able to read and speak English\n* No condition that compromises compliance with the objectives and procedures of this study, as judged by the principal investigator\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior chemotherapy, CNS radiotherapy, or intrathecal therapy\n* Premenopausal women receiving aromatase inhibitors must also be receiving ovarian suppression\n* No concurrent narcotics or major antipsychotic medications that may impair cognition",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}